Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2

International Journal of Cancer

Volumn 99, Issue 1, 2002, Pages 93-99

  Meij, Pauline ^a   Leen, Ann ^b   Rickinson, Alan B ^b   Verkoeijen, Saertje ^a   Vervoort, Marcel B H J ^a   Bloemena, Elisabeth ^a   Middeldorp, Jaap M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

CTL; Epstein Barr virus; LMP1; LMP2

Indexed keywords

CD8 ANTIGEN; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; NUCLEAR ANTIGEN 1; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS CARCINOGENESIS;

ANTIGENS, VIRAL; CAPSID; CD8-POSITIVE T-LYMPHOCYTES; HERPESVIRUS 4, HUMAN; HUMANS; PEPTIDES; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

EID: 0036568499     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10309     Document Type: Article

References (41)

1. Epstein-Barr virus
2. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease
3. Epstein-Barr latent membrane protein expression in Hodgkin and Reed-Sternberg cells
4. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis
5. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNAI, LMP1 and LMP2 transcripts
6. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: Expression of the transforming BARF1 gene
7. Expression of BAFR1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies
8. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen 1
9. Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and aminoterminal cytoplasmic domains necessary for effects in B-lymphoma cells
10. An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase
11. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): Evidence for HLA A2 supertype restricted immune recognition of EBV-infected cells by LMPl-specific cytotoxic T lymphocytes
12. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
13. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: Implications for immune-mediated therapy of EBV+ Hodgkin's disease
14. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases
15. +, interferon-γ-secreting, T lymphocytes
16. Vaccine strategies against Epstein-Barr virus-associated diseases: Lessons from studies on cytotoxic T-cell mediated immune regulation
17. Transporter (TAP)-independent processing of a multiple membrane- spanning protein, the Epstein-Barr virus latent membrane protein 2
18. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies
19. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell independent pathway
20. + responses to Epstein-Barr virus antigens
21. + T lymphocytes from human blood
22. + T cell response: Lessons from the EBV nuclear antigen EBNA1
23. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases
24. Scheme for ranking potential HLA-A2 peptides based on independent binding of individual peptide side-chains
25. Conserved (CTL) epitopes within EBV latent membrane protein 2, a potential target for CTL-based tumour therapy
26. Role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative diseases following transplantation
27. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells
28. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: Implications for T-cell-based therapy
29. + T-cells specific for EBV in healthy carriers
30. Sequence analysis of the Epstein-Barr virus latent membrane protein 1 gene and promoter region: Identification of four variants among wild type EBV isolates
31. Expression of the Epstein-Barr virus latent membrane protein (LMP) in insect cells and detection of antibodies in human sera against this protein
32. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases
33. Antibodies to LMP2A/2B in EBV-carrying malignancies
34. Characterization of the antibody response to the latent infection terminal protein of Epstein-Barr virus in patients with nasopharyngeal carcinoma
35. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses
36. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1
37. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state
38. Dendritic cells and the control of immunity
39. Strategies involved in developing an effective vaccine to EBV-associated diseases
40. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
41. Accessing Epstein-Barr virus-specific T cell memory with peptide-loaded dendritic cells